Neuregulin-1 induces cancer stem cell characteristics in breast cancer cell lines

Jeong,Hoiseon; Kim,Jinkyoung; Lee,Youngseok; Seo,Jae  Hong; Hong,Sung  Ran; Kim,Aeree

doi:10.3892/or.2014.3330

Neuregulin-1 induces cancer stem cell characteristics in breast cancer cell lines

Authors:
- Hoiseon Jeong
- Jinkyoung Kim
- Youngseok Lee
- Jae Hong Seo
- Sung Ran Hong
- Aeree Kim
View Affiliations

Affiliations: Department of Pathology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine, Jung-gu, Seoul 100-380, Republic of Korea , Department of Pathology, Korea University Guro Hospital, Korea University College of Medicine, Guro-gu, Seoul 152-703, Republic of Korea, Division of Hematology-Oncology, Department of Medicine, Korea University Guro Hospital, Korea University College of Medicine, Guro-gu, Seoul 152-703, Republic of Korea
Published online on: July 11, 2014 https://doi.org/10.3892/or.2014.3330
Pages: 1218-1224

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In breast cancer, neuregulin-1 (NRG1) is known as a ligand for the HER3 receptor, which has no intrinsic tyrosine kinase activity. When activated by NRG1 binding, the HER3 receptor forms a heterodimer with other HER family receptors and mediates downstream signaling pathways, leading to multiple effects including growth, proliferation, decreased apoptosis, cellular migration and angiogenesis. Cancer stem cells (CSCs), a subgroup of cancer cells, are considered to have features of stem cells such as self-renewal ability and pluripotent differentiation into other types of mature cells. This study showed that NRG1 treatment induced CSC characteristics in breast cancer cell lines. Using breast cancer cell lines, MCF-7, SKBr-3 and MDA-MB 468, changes related to CSC characteristics were analyzed. Flow cytometry was used to analyze changes in CSC fractions in multiple cell lines after NRG1 treatment. Western blot analysis and immunofluorescence staining demonstrated the expression of CSC markers. To confirm that NRG1 treatment acts through the HER3 receptor, inhibition studies using small interfering RNA (siRNA) were performed. In MCF-7 and SKBr-3 cells, increases in the CSC fraction and expression of CSC markers were observed after NRG1 treatment. However, MDA-MB 468 cells showed high intrinsic expression of CSC markers and a high cellular fraction of CSCs, and in these cells, NRG1 treatment caused no significant change in CSC characteristics. Inhibition of the HER3 receptor blocked the NRG1-induced CSC characteristics, indicating that NRG1 functions through the HER3 receptor. The results imply the presence of a mechanism by which the HER receptors, activated by NRG1, contribute to the acquisition of CSC-like characteristics in some types of breast cancer.

View Figures

View References

1	Holmes WE, Sliwkowski MX, Akita RW, et al: Identification of heregulin, a specific activator of p185erbB2. Science. 256:1205–1210. 1992. View Article : Google Scholar : PubMed/NCBI
2	Britsch S: The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol. 190:1–65. 2007.PubMed/NCBI
3	Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C and Lupu R: Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res. 1:165–175. 2003.PubMed/NCBI
4	Vijapurkar U, Kim MS and Koland JG: Roles of mitogen-activated protein kinase and phosphoinositide 3′-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling. Exp Cell Res. 284:291–302. 2003.
5	Hsieh AC and Moasser MM: Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 97:453–457. 2007. View Article : Google Scholar : PubMed/NCBI
6	Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
7	Lupu R, Cardillo M, Cho C, et al: The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat. 38:57–66. 1996. View Article : Google Scholar : PubMed/NCBI
8	Hijazi MM, Thompson EW, Tang C, et al: Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines. Int J Oncol. 17:629–641. 2000.PubMed/NCBI
9	Cheng L, Zha Z, Lang B, Liu J and Yao X: Heregulin-beta1 promotes metastasis of breast cancer cell line SKBr-3 through upregulation of Snail and induction of epithelial-mesenchymal transition. Cancer Lett. 280:50–60. 2009. View Article : Google Scholar : PubMed/NCBI
10	Yuan G, Qian L, Song L, et al: Heregulin-beta promotes matrix metalloproteinase-7 expression via HER2-mediated AP-1 activation in MCF-7 cells. Mol Cell Biochem. 318:73–79. 2008. View Article : Google Scholar : PubMed/NCBI
11	Cho SJ, Chae MJ, Shin BK, Kim HK and Kim A: Akt- and MAPK-mediated activation and secretion of MMP-9 into stroma in breast cancer cells upon heregulin treatment. Mol Med Rep. 1:83–88. 2008.PubMed/NCBI
12	Guarino M, Rubino B and Ballabio G: The role of epithelial- mesenchymal transition in cancer pathology. Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
13	Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW and Waltham M: Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and in vivo. Cells Tissues Organs. 185:191–203. 2007. View Article : Google Scholar : PubMed/NCBI
14	Micalizzi DS, Farabaugh SM and Ford HL: Epithelial- mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 15:117–134. 2010. View Article : Google Scholar : PubMed/NCBI
15	Ebben JD, Treisman DM, Zorniak M, Kutty RG, Clark PA and Kuo JS: The cancer stem cell paradigm: a new understanding of tumor development and treatment. Expert Opin Ther Targets. 14:621–632. 2010. View Article : Google Scholar : PubMed/NCBI
16	Blick T, Hugo H, Widodo E, et al: Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24(lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia. 15:235–252. 2010. View Article : Google Scholar : PubMed/NCBI
17	Creighton CJ, Chang JC and Rosen JM: Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia. 15:253–260. 2010. View Article : Google Scholar : PubMed/NCBI
18	Mani SA, Guo W, Liao MJ, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
19	May CD, Sphyris N, Evans KW, Werden SJ, Guo W and Mani SA: Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res. 13:2022011. View Article : Google Scholar : PubMed/NCBI
20	Almqvist PM, Mah R, Lendahl U, Jacobsson B and Hendson G: Immunohistochemical detection of nestin in pediatric brain tumors. J Histochem Cytochem. 50:147–158. 2002. View Article : Google Scholar : PubMed/NCBI
21	Dahlstrand J, Collins VP and Lendahl U: Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res. 52:5334–5341. 1992.PubMed/NCBI
22	Miyazono K: Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci. 85:314–323. 2009. View Article : Google Scholar : PubMed/NCBI
23	Taylor MA, Parvani JG and Schiemann WP: The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia. 15:169–190. 2010. View Article : Google Scholar : PubMed/NCBI
24	Wang H, Wu J, Zhang Y, et al: Transforming growth factor β-induced epithelial-mesenchymal transition increases cancer stem-like cells in the PANC-1 cell line. Oncol Lett. 3:229–233. 2012.
25	Hardy KM, Booth BW, Hendrix MJ, Salomon DS and Strizzi L: ErbB/EGF signaling and EMT in mammary development and breast cancer. J Mammary Gland Biol Neoplasia. 15:191–199. 2010. View Article : Google Scholar : PubMed/NCBI
26	Kim J, Jung J, Lee SJ, Lee JS and Park MJ: Cancer stem-like cells persist in established cell lines through autocrine activation of EGFR signaling. Oncol Lett. 3:607–612. 2012.PubMed/NCBI
27	Li Y and Laterra J: Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res. 72:576–580. 2012. View Article : Google Scholar : PubMed/NCBI
28	Levenson AS and Jordan VC: MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res. 57:3071–3078. 1997.PubMed/NCBI
29	Lacroix M and Leclercq G: Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat. 83:249–289. 2004. View Article : Google Scholar : PubMed/NCBI
30	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
31	Cariati M, Naderi A, Brown JP, et al: Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF-7 breast cancer cell line. Int J Cancer. 122:298–304. 2008. View Article : Google Scholar : PubMed/NCBI
32	Shackleton M, Vaillant F, Simpson KJ, et al: Generation of a functional mammary gland from a single stem cell. Nature. 439:84–88. 2006. View Article : Google Scholar : PubMed/NCBI
33	Taddei I, Deugnier MA, Faraldo MM, et al: Beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat Cell Biol. 10:716–722. 2008. View Article : Google Scholar : PubMed/NCBI
34	White DE, Kurpios NA, Zuo D, et al: Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell. 6:159–170. 2004. View Article : Google Scholar
35	Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G and Palacios J: Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 68:989–997. 2008. View Article : Google Scholar
36	Jeong H, Ryu YJ, An J, Lee Y and Kim A: Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology. 60:E87–E95. 2012. View Article : Google Scholar
37	Kim S, Choi JH, Lim HI, et al: EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBr-3 breast cancer cell line. Cell Signal. 21:892–898. 2009. View Article : Google Scholar : PubMed/NCBI
38	Park S, Jung HH, Park YH, Ahn JS and Im YH: ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression. Biochem Biophys Res Commun. 407:680–686. 2011. View Article : Google Scholar : PubMed/NCBI
39	Frogne T, Benjaminsen RV, Sonne-Hansen K, et al: Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat. 114:263–275. 2009. View Article : Google Scholar : PubMed/NCBI
40	Garrett JT, Olivares MG, Rinehart C, et al: Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA. 108:5021–5026. 2011. View Article : Google Scholar : PubMed/NCBI
41	Sergina NV, Rausch M, Wang D, et al: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 445:437–441. 2007. View Article : Google Scholar : PubMed/NCBI